Healthcare Industry News:  SQI Diagnostics 

Diagnostics Personnel

 News Release - September 30, 2013

SQI Diagnostics Announces Changes to Its Board of Directors

TORONTO--(Healthcare Sales & Marketing Network)--SQI Diagnostics’ Inc. (SQD.V) Board of Directors is pleased to announce the appointment of Andrew Morris, President and CEO of SQI Diagnostics to the Board of Directors.

Andrew Morris has been with SQI for over nine years and acted as the Company’s Chief Financial Officer prior to being promoted to President and CEO in June, 2013. Mr. Morris’s in-depth knowledge of the operations and his track record in the day-to-day management of SQI Diagnostics’ business functions will be valuable assets to the Board.

Mr. Morris replaces Dr. Peter Lea who has resigned from the Board, effective immediately. Dr. Lea will continue as an active, non-voting senior advisor to the Board. Dr. Lea founded SQI Diagnostics in 1999 and invented and patented the core technology underpinning SQI’s multiplexing microarray technology and is actively involved day to day in the role of Founder.

“The Board would like to thank Dr. Lea for his years of service to the Board and value his ongoing contributions to the leadership of SQI,” said Claude Ricks, chairman of SQI’s Board of Directors. “We are pleased to have Mr. Morris as a member of the Board of Directors. His insight, experience and leadership will assist the Board in guiding the emerging success of SQI."

About SQI Diagnostics

SQI Diagnostics is a life sciences and diagnostics company serving the reference lab testing and pharmaceutical development markets. The Company’s proprietary multiplexed tests and fully automated systems decrease costs, simplify workflows, increase throughput and decrease time to results for labs conducting antibody and biomarker testing.

For more information about SQI Diagnostics’ please visit www.sqidiagnostics.com.

FORWARD-LOOKING INFORMATION

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “believe”, “in the process”, “is subject to” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the ability of our patents to adequately protect our rights or permit us to gain or keep any competitive advantage, and our ability to market and sell our novel multiplexing technologies and detection platforms. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Source: SQI Diagnostics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.